Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289210 · ClinicalTrials.gov registry record · Phase 1
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01289210: Clinical Trial Phase 1 study, sponsored by Celgene.
NCT01289210 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01289210, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.
Primary Outcome
Tumor response was assessed via CT scans of the chest, abdomen, pelvis or other medically appropriate imaging modality to evaluate all areas of disease. Cheson Criteria were used for calculation of response.
Interventions
- DRUG VTX-2337 plus radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Why NCT01289210 stopped before completion
NCT01289210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which VTX-2337 plus radiotherapy is the first listed.
NCT01289210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01289210 about?
NCT01289210 is a clinical study titled "VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas". This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections ...
What is the current status of trial NCT01289210?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2011-07. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01289210?
The interventions under investigation include: VTX-2337 plus radiotherapy (DRUG).
Who is sponsoring clinical trial NCT01289210?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01289210's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia